Argent BioPharma Limited (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company, is pioneering a transformative approach to drug-resistant epilepsy with its innovative therapy, CannEpil®. Designed as a high-CBD, low-THC oral mucosal solution, CannEpil® is proving to be a lifeline for patients with refractory epilepsy, offering renewed hope where conventional treatments have failed.

For approximately 30% of epilepsy patients, seizures persist despite standard therapies, significantly impacting their quality of life. CannEpil® is engineered to reduce seizure frequency and severity while minimizing psychoactive effects, making it a breakthrough alternative for individuals with drug-resistant epilepsy.

The therapy’s potential is underscored by the precedent set by GW Pharmaceuticals’ $7.2 billion acquisition, which highlighted the growing recognition of cannabis-based epilepsy treatments. Argent BioPharma is positioned to follow a similar trajectory, expanding global access to safe, effective cannabinoid-based solutions for severe epilepsy.

The UK has taken a significant step in advancing epilepsy care with the first patient receiving CannEpil® under the NHS’s Refractory Epilepsy Specialist Clinical Advisory Service (RESCAS). This milestone was achieved in collaboration with the I AM Billy Foundation, an advocacy group inspired by Billy Caldwell, whose case sparked national awareness about medical cannabis for epilepsy treatment.

Additionally, CannEpil®’s inclusion in the Named Patient Request system ensures that doctors registered with the General Medical Council (GMC) can prescribe it to patients with urgent medical needs, creating a crucial pathway for epilepsy sufferers to access life-changing treatment.

CannEpil® has undergone extensive clinical testing to ensure both efficacy and safety, setting a new benchmark in cannabinoid-based seizure management. A notable Australian study confirmed that CannEpil® does not impair driving performance, offering patients and caregivers confidence in its day-to-day usability.

Previously launched in Ireland under full governmental health insurance coverage, CannEpil® continues to gain international recognition, reinforcing its role as a game-changer in refractory epilepsy treatment.

With growing acceptance and increasing availability, CannEpil® is poised to redefine epilepsy care worldwide, bridging the gap for patients who have exhausted all other treatment options.